289 related articles for article (PubMed ID: 33640878)
1. Elevated frequencies of CD14
Xue G; Jiang M; Zhao R; Le A; Li J
Aging (Albany NY); 2021 Feb; 13(5):6236-6246. PubMed ID: 33640878
[TBL] [Abstract][Full Text] [Related]
2. The CD14
Mengos AE; Gastineau DA; Gustafson MP
Front Immunol; 2019; 10():1147. PubMed ID: 31191529
[TBL] [Abstract][Full Text] [Related]
3. Activated Circulating Myeloid-Derived Suppressor Cells in Patients with Dilated Cardiomyopathy.
Zhang WC; Wang YG; Wei WH; Xiong X; Liu KL; Wang DH; Hu XF; Peng YD; Wu JJ; Cheng LX
Cell Physiol Biochem; 2016; 38(6):2438-51. PubMed ID: 27287545
[TBL] [Abstract][Full Text] [Related]
4. CD14, CD16 and HLA-DR reliably identifies human monocytes and their subsets in the context of pathologically reduced HLA-DR expression by CD14(hi) /CD16(neg) monocytes: Expansion of CD14(hi) /CD16(pos) and contraction of CD14(lo) /CD16(pos) monocytes in acute liver failure.
Abeles RD; McPhail MJ; Sowter D; Antoniades CG; Vergis N; Vijay GK; Xystrakis E; Khamri W; Shawcross DL; Ma Y; Wendon JA; Vergani D
Cytometry A; 2012 Oct; 81(10):823-34. PubMed ID: 22837127
[TBL] [Abstract][Full Text] [Related]
5. CD14
Bernsmeier C; Triantafyllou E; Brenig R; Lebosse FJ; Singanayagam A; Patel VC; Pop OT; Khamri W; Nathwani R; Tidswell R; Weston CJ; Adams DH; Thursz MR; Wendon JA; Antoniades CG
Gut; 2018 Jun; 67(6):1155-1167. PubMed ID: 28592438
[TBL] [Abstract][Full Text] [Related]
6. Increased circulating CD14(+)HLA-DR-/low myeloid-derived suppressor cells are associated with poor prognosis in patients with small-cell lung cancer.
Tian T; Gu X; Zhang B; Liu Y; Yuan C; Shao L; Guo Y; Fan K
Cancer Biomark; 2015; 15(4):425-32. PubMed ID: 25792471
[TBL] [Abstract][Full Text] [Related]
7. Immunosuppressive CD14+HLA-DRlow/neg IDO+ myeloid cells in patients following allogeneic hematopoietic stem cell transplantation.
Mougiakakos D; Jitschin R; von Bahr L; Poschke I; Gary R; Sundberg B; Gerbitz A; Ljungman P; Le Blanc K
Leukemia; 2013 Feb; 27(2):377-88. PubMed ID: 22828446
[TBL] [Abstract][Full Text] [Related]
8. Vasoactive intestinal peptide induces CD14+HLA-DR‑/low myeloid-derived suppressor cells in gastric cancer.
Li G; Wu K; Tao K; Lu X; Ma J; Mao Z; Li H; Shi L; Li J; Niu Y; Xiang F; Wang G
Mol Med Rep; 2015 Jul; 12(1):760-8. PubMed ID: 25695487
[TBL] [Abstract][Full Text] [Related]
9. CD33
Sun Y; Shao J; Jiang F; Wang Y; Yan Q; Yu N; Zhang J; Zhang J; Li M; He Y
Am J Reprod Immunol; 2019 Jan; 81(1):e13067. PubMed ID: 30375700
[TBL] [Abstract][Full Text] [Related]
10. Circulating CD14
Stenzel AE; Abrams SI; Joseph JM; Goode EL; Tario JD; Wallace PK; Kaur D; Adamson AK; Buas MF; Lugade AA; Laslavic A; Taylor SE; Orr B; Edwards RP; Elishaev E; Odunsi K; Mongiovi JM; Etter JL; Winham SJ; Kaufmann SH; Modugno F; Moysich KB
Am J Reprod Immunol; 2021 Mar; 85(3):e13343. PubMed ID: 32905653
[TBL] [Abstract][Full Text] [Related]
11. CLL-cells induce IDOhi CD14+HLA-DRlo myeloid-derived suppressor cells that inhibit T-cell responses and promote TRegs.
Jitschin R; Braun M; Büttner M; Dettmer-Wilde K; Bricks J; Berger J; Eckart MJ; Krause SW; Oefner PJ; Le Blanc K; Mackensen A; Mougiakakos D
Blood; 2014 Jul; 124(5):750-60. PubMed ID: 24850760
[TBL] [Abstract][Full Text] [Related]
12. Increased CD14(+)HLA-DR (-/low) myeloid-derived suppressor cells correlate with extrathoracic metastasis and poor response to chemotherapy in non-small cell lung cancer patients.
Huang A; Zhang B; Wang B; Zhang F; Fan KX; Guo YJ
Cancer Immunol Immunother; 2013 Sep; 62(9):1439-51. PubMed ID: 23760662
[TBL] [Abstract][Full Text] [Related]
13. Increase in CD14+HLA-DR -/low myeloid-derived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis.
Arihara F; Mizukoshi E; Kitahara M; Takata Y; Arai K; Yamashita T; Nakamoto Y; Kaneko S
Cancer Immunol Immunother; 2013 Aug; 62(8):1421-30. PubMed ID: 23764929
[TBL] [Abstract][Full Text] [Related]
14. A circulating subpopulation of monocytic myeloid-derived suppressor cells as an independent prognostic/predictive factor in untreated non-small lung cancer patients.
Vetsika EK; Koinis F; Gioulbasani M; Aggouraki D; Koutoulaki A; Skalidaki E; Mavroudis D; Georgoulias V; Kotsakis A
J Immunol Res; 2014; 2014():659294. PubMed ID: 25436215
[TBL] [Abstract][Full Text] [Related]
15. The clinical and prognostic significance of CD14(+)HLA-DR(-/low) myeloid-derived suppressor cells in hepatocellular carcinoma patients receiving radiotherapy.
Wang D; An G; Xie S; Yao Y; Feng G
Tumour Biol; 2016 Aug; 37(8):10427-33. PubMed ID: 26846107
[TBL] [Abstract][Full Text] [Related]
16. Tumor-induced CD14+HLA-DR (-/low) myeloid-derived suppressor cells correlate with tumor progression and outcome of therapy in multiple myeloma patients.
Wang Z; Zhang L; Wang H; Xiong S; Li Y; Tao Q; Xiao W; Qin H; Wang Y; Zhai Z
Cancer Immunol Immunother; 2015 Mar; 64(3):389-99. PubMed ID: 25548095
[TBL] [Abstract][Full Text] [Related]
17. Immunosuppressive activity of CD14+ HLA-DR- cells in squamous cell carcinoma of the head and neck.
Chikamatsu K; Sakakura K; Toyoda M; Takahashi K; Yamamoto T; Masuyama K
Cancer Sci; 2012 Jun; 103(6):976-83. PubMed ID: 22360618
[TBL] [Abstract][Full Text] [Related]
18. Immunosuppressive myeloid-derived suppressor cells are increased in splenocytes from cancer patients.
Jordan KR; Kapoor P; Spongberg E; Tobin RP; Gao D; Borges VF; McCarter MD
Cancer Immunol Immunother; 2017 Apr; 66(4):503-513. PubMed ID: 28108766
[TBL] [Abstract][Full Text] [Related]
19. Activated human hepatic stellate cells induce myeloid derived suppressor cells from peripheral blood monocytes in a CD44-dependent fashion.
Höchst B; Schildberg FA; Sauerborn P; Gäbel YA; Gevensleben H; Goltz D; Heukamp LC; Türler A; Ballmaier M; Gieseke F; Müller I; Kalff J; Kurts C; Knolle PA; Diehl L
J Hepatol; 2013 Sep; 59(3):528-35. PubMed ID: 23665041
[TBL] [Abstract][Full Text] [Related]
20. Increased CD14
Wang Z; Zhu F; Wang J; Tao Q; Xu X; Wang H; Xiong S; Wang Y; Zhai Z
Front Immunol; 2019; 10():1202. PubMed ID: 31231374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
